CA3254890A1 - METHOD FOR STERILIZING AND PACKAGING A PHARMACEUTICAL PREPARATION - Google Patents
METHOD FOR STERILIZING AND PACKAGING A PHARMACEUTICAL PREPARATIONInfo
- Publication number
- CA3254890A1 CA3254890A1 CA3254890A CA3254890A CA3254890A1 CA 3254890 A1 CA3254890 A1 CA 3254890A1 CA 3254890 A CA3254890 A CA 3254890A CA 3254890 A CA3254890 A CA 3254890A CA 3254890 A1 CA3254890 A1 CA 3254890A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- salt
- aqueous pharmaceutical
- container
- benzodiazepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
- A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
- A61L2/022—Filtration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2103/00—Materials or objects being the target of disinfection or sterilisation
- A61L2103/05—Living organisms or biological materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hematology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022056765 | 2022-03-30 | ||
| JP2022-056765 | 2022-03-30 | ||
| PCT/JP2023/012751 WO2023190653A1 (ja) | 2022-03-30 | 2023-03-29 | 医薬製剤の滅菌法と包装体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3254890A1 true CA3254890A1 (en) | 2025-04-09 |
Family
ID=88202031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3254890A Pending CA3254890A1 (en) | 2022-03-30 | 2023-03-29 | METHOD FOR STERILIZING AND PACKAGING A PHARMACEUTICAL PREPARATION |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250213588A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4501329A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2023190653A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240165977A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118946362A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3254890A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202404607A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023190653A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250214992A1 (en) * | 2022-03-30 | 2025-07-03 | Santen Pharmaceutical Co., Ltd. | High-purity compound production method and purification method |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0318772A (ja) | 1989-06-16 | 1991-01-28 | Mitsubishi Cable Ind Ltd | 絶縁体の絶緑性能評価方法 |
| US5716952A (en) | 1992-03-18 | 1998-02-10 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| WO2018039159A1 (en) * | 2016-08-22 | 2018-03-01 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combination |
| EP4178948A2 (en) * | 2020-07-29 | 2023-05-17 | Universidade de Santiago de Compostela | Functionalized isonitriles and products, preparation and uses thereof |
| CA3189821A1 (en) * | 2020-08-04 | 2022-02-10 | Santen Pharmaceutical Co., Ltd. | Agent for treating myopia, preventing myopia and/or suppressing myopia progression |
| JP7253813B2 (ja) | 2020-08-07 | 2023-04-07 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
| KR20230087514A (ko) * | 2020-10-14 | 2023-06-16 | 산텐 세이야꾸 가부시키가이샤 | 안정한 의약 조성물 |
-
2023
- 2023-03-29 JP JP2024512652A patent/JPWO2023190653A1/ja active Pending
- 2023-03-29 CN CN202380030713.XA patent/CN118946362A/zh active Pending
- 2023-03-29 CA CA3254890A patent/CA3254890A1/en active Pending
- 2023-03-29 TW TW112111985A patent/TW202404607A/zh unknown
- 2023-03-29 KR KR1020247034479A patent/KR20240165977A/ko active Pending
- 2023-03-29 WO PCT/JP2023/012751 patent/WO2023190653A1/ja not_active Ceased
- 2023-03-29 US US18/851,269 patent/US20250213588A1/en active Pending
- 2023-03-29 EP EP23780662.5A patent/EP4501329A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250213588A1 (en) | 2025-07-03 |
| CN118946362A (zh) | 2024-11-12 |
| JPWO2023190653A1 (cg-RX-API-DMAC7.html) | 2023-10-05 |
| KR20240165977A (ko) | 2024-11-25 |
| EP4501329A1 (en) | 2025-02-05 |
| EP4501329A4 (en) | 2026-03-25 |
| TW202404607A (zh) | 2024-02-01 |
| WO2023190653A1 (ja) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7265584B2 (ja) | 高眼圧症及び緑内障を治療するための方法及び組成物 | |
| KR101846804B1 (ko) | 리파수딜 함유 수성 조성물을 위한 의약 제제 | |
| EP3603642B1 (en) | Pharmaceutical preparation | |
| US20220096434A1 (en) | Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations | |
| JP7045359B2 (ja) | 医薬製剤 | |
| JP2025524100A (ja) | 眼科用局所クリーム製剤及びその使用 | |
| JP2024169649A (ja) | 水性組成物 | |
| JP2022163031A (ja) | 医薬(2) | |
| EP4501329A1 (en) | Sterilization method of pharmaceutical preparation and packaging | |
| KR20170093839A (ko) | 수성 조성물 | |
| JP2022101629A (ja) | 安定な医薬組成物 | |
| JP2023181428A (ja) | 眼科用組成物 | |
| WO2021195256A1 (en) | Pharmaceutical preparation | |
| US20150366966A1 (en) | Stable Aqueous Solution | |
| EP4512404A1 (en) | Composition for ophthalmic use containing sepetaprost | |
| JP7464675B2 (ja) | 医薬品製剤(2) | |
| TW202517277A (zh) | 含有賽佩普斯特(Sepetaprost)之點眼液 | |
| JP2026027212A (ja) | 水性組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240924 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250122 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250213 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250213 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250213 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250220 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION) Effective date: 20250409 |